<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673826</url>
  </required_header>
  <id_info>
    <org_study_id>HO147</org_study_id>
    <secondary_id>2017-000555-10</secondary_id>
    <nct_id>NCT03673826</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM</brief_title>
  <acronym>HO147SMM</acronym>
  <official_title>Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be&#xD;
      enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2,&#xD;
      lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9) or Rd combination&#xD;
      (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9);&#xD;
      followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      A recent study has shown that intervention with the use of novel agents in smoldering myeloma&#xD;
      (SMM) resulted in prolonged PFS and OS without significant toxicity. A more recent pilot&#xD;
      study in high-risk smoldering myeloma using carfilzomib, lenalidomide in combination with&#xD;
      dexamethasone resulted in 100% CR rate and 10 out of 12 patients reached MRD negativity.&#xD;
      These studies formed the rationale to compare the efficacy and safety of carfilzomib,&#xD;
      lenalidomide and dexamethasone vs. lenalidomide, dexamethasone, both followed by 24 months of&#xD;
      lenalidomide maintenance in high-risk SMM.&#xD;
&#xD;
      This study is designed to compare 2 treatment modalities to find the optimal treatment in&#xD;
      efficacy and safety for highrisk SMM, to define new risk stratifiers for outcome to treatment&#xD;
      in SMM and to better understand the biology of SMM.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      The primary objective of the study is :&#xD;
&#xD;
      To assess the progression-free survival rate of KRd versus Rd in patients with high-risk SMM&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To assess MRD status after 4 and 9 cycles induction treatment&#xD;
&#xD;
        -  To assess the correlation between PFS and MRD&#xD;
&#xD;
        -  To determine progression-free survival-2 (PFS2 )&#xD;
&#xD;
        -  To determine duration of response (DOR)&#xD;
&#xD;
        -  To determine overall survival (OS)&#xD;
&#xD;
        -  To assess correlation of MRD status with PFS2, DOR and OS To evaluate toxicity of&#xD;
           combination therapy (carfilzomib, lenalidomide, and dexamethasone).&#xD;
&#xD;
        -  To evaluate disease heterogeneity in relation to clinical outcomes (molecular profiling&#xD;
           on bone marrow samples)&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Randomized multi-center open-label phase 2 trial.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients with high-risk SMM, age 18 years or older&#xD;
&#xD;
      Intervention (if applicable):&#xD;
&#xD;
      Patients will be treated with KRd combination 9 cycles a 28 days (carfilzomib , lenalidomide&#xD;
      , dexamethasone) or Rd combination (lenalidomide , dexamethasone ); followed by extended&#xD;
      lenalidomide dosing (for 24 cycles a 28 days).&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      - Progression-free survival rate, defined as time from study entry to progression or death,&#xD;
      whichever comes first;&#xD;
&#xD;
      Secundary study parameters/outcome of the study (if applicable):&#xD;
&#xD;
        -  MRD status after induction cycle 4 and 9,&#xD;
&#xD;
        -  Progression-free survival-2 (PFS2), defined at time from randomization to progression&#xD;
           after second-line treatment or death, whichever comes first;&#xD;
&#xD;
        -  Duration of response (DOR), defined as time from response to progression or death,&#xD;
           whichever comes first;&#xD;
&#xD;
        -  Overall survival (OS), defined as time from study entry to death from any cause.&#xD;
           Patients still alive at the date last contact will be censored;&#xD;
&#xD;
        -  Correlation of MRD status with PFS, PFS2, DOR and OS;&#xD;
&#xD;
        -  Toxicity of combination therapy (carfilzomib, lenalidomide, and dexamethasone). Nature&#xD;
           and extent of the burden and risks associated with participation, benefit and group&#xD;
           relatedness (if applicable): Given the high rates of progression specific to the high&#xD;
           risk SMM populations and low toxicity profile of combination therapy, risk of exposure&#xD;
           does not seem to outweigh the clinical benefit that patients may derive from therapy.&#xD;
           More importantly, much of patient morbidity in MM is associated with pain from&#xD;
           irreversible skeletal related events. This study aims to treat or cure the disease&#xD;
           before irreversible bone damage occurs or before aggressive clinical MM occurs.&#xD;
&#xD;
      Discomfort from venipuncture, bone marrow biopsy, and CT scan is minimal and of limited risk&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>Until 5 years after randomization or death, whatever comes first</time_frame>
    <description>Time from study entry to progression or death, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRD status</measure>
    <time_frame>9 months</time_frame>
    <description>MRD assessment by immunophenotyping in bone marrow after induction cycles 4 and 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival-2 (PFS2),</measure>
    <time_frame>Until 5 years after randomization or death, whatever comes first</time_frame>
    <description>Time from randomization to progression after second-line treatment or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR),</measure>
    <time_frame>Until 5 years after randomization or death, whatever comes first</time_frame>
    <description>Time from response to progression or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Until 5 years after randomization or death, whatever comes first</time_frame>
    <description>Time from study entry to death from any cause. Patients still alive at the date last contact will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD status correlation</measure>
    <time_frame>Until 5 years after randomization or death, whatever comes first</time_frame>
    <description>Correlation of MRD status with PFS, PFS2, DOR and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of combination therapy with Carfilzomib. Lenalidomide and Dexamethasone</measure>
    <time_frame>Through induction treatment and extrended treatment, up to 3 years after randomization</time_frame>
    <description>Measured by tabulation of the incidence of adverse events with CTCAE grade 1 or more, separately for induction treatment and for extended treatment, by randomization arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Smouldering Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>9 cycles 20/36mg/m2 days 1,2,8,9,15,16</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed Smoldering Multiple&#xD;
             Myeloma based on the 2014 International Myeloma Working Group Criteria(20):&#xD;
&#xD;
          -  Serum M-protein ≥3.0 g/dl, or urinary monoclonal protein &gt;500 mg per 24 hours, and/or&#xD;
             monoclonal bone marrow plasma cells ≥10-60 %&#xD;
&#xD;
          -  Absence of CRAB symptoms:&#xD;
&#xD;
          -  anemia: Hemoglobin &lt;6.2 mmol/L (10 g/dl) or a hemoglobin value of &gt;1.2 mmol/L (2 g/dL)&#xD;
             below the lower limit of normal&#xD;
&#xD;
          -  renal failure: serum creatinine &gt; 2.0 mg/dL or creatinine clearance &lt; 40 ml/min&#xD;
&#xD;
          -  hypercalcemia: serum calcium &gt;0·25 mmol/L (&gt;1 mg/dL) higher than the upper limit of&#xD;
             normal or &gt;2·75 mmol/L (&gt;11 mg/dL)&#xD;
&#xD;
          -  Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT&#xD;
&#xD;
          -  Absence of myeloma defining events:&#xD;
&#xD;
          -  Involved/uninvolved serum free light chain ratio ≥100 with involved free light-chain&#xD;
             concentration ≥10 mg/dl&#xD;
&#xD;
          -  Presence of 2 or more focal lesions by MRI (2 of which at least 5 mm)&#xD;
&#xD;
          -  Clonal bone marrow plasma cell percentage ≥60%&#xD;
&#xD;
          -  Patients must have high risk Smoldering Multiple Myeloma based on the Mayo Clinic&#xD;
             and/or the PETHEMA criteria:&#xD;
&#xD;
          -  3 factors of Mayo Clinic criteria:&#xD;
&#xD;
          -  Bone marrow plasma cells ≥10 %&#xD;
&#xD;
          -  Serum M-protein ≥ 3 g/dl&#xD;
&#xD;
          -  Serum free light-chain ratio &lt;0.125 or &gt;8&#xD;
&#xD;
          -  And/or 2 factors of PETHEMA criteria:&#xD;
&#xD;
          -  Of the plasma cell population ≥95% abnormal plasma cells (presence or absence of CD38,&#xD;
             CD56, CD19 and/or CD45)&#xD;
&#xD;
          -  Immunoparesis, a reduction (below the lower normal limit) in the levels of 1 or 2 of&#xD;
             the uninvolved immunoglobulins (Ig)&#xD;
&#xD;
          -  Measurable disease defined by any one of the following:&#xD;
&#xD;
          -  Serum monoclonal protein ≥ 1.0 g/dl&#xD;
&#xD;
          -  Urine monoclonal protein &gt;200 mg/24 hour&#xD;
&#xD;
          -  Serum immunoglobulin free light chain &gt;10 mg/dL AND abnormal kappa/lambda ratio&#xD;
             (reference 0.26-1.65)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  WHO/ECOG performance status &lt;2 (see Appendix C).&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
          -  Absolute neutrophil count &gt;1.0 x109 /L&#xD;
&#xD;
          -  Platelets ≥75 ×109 /L&#xD;
&#xD;
          -  Hemoglobin ≥10 g/dL (&gt;6.2 mmol/l)&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 x institutional upper limit of normal&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) ≤3.0 × institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine Clearance ≥ 50 ml/min. CrCl will be calculated by Cockcroft-Gault method or&#xD;
             eGFR (Modified Diet in Renal Disease [MDRD])&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 10 - 14 days prior to entry and again within 24 hours of starting lenalidomide&#xD;
             treatment; (see 9.1.4)&#xD;
&#xD;
          -  Patients must be willing and capable to use adequate contraception during and after&#xD;
             the therapy (all men, all pre-menopausal women) (see 9.1.4.); Patients must be able to&#xD;
             adhere to the requirements of the Lenalidomide Clinical Trial Pregnancy Prevention&#xD;
             Plan;&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient is capable of giving informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patients with symptomatic multiple myeloma (i.e. having myeloma defining events)&#xD;
&#xD;
          -  Amyloid Light-chain (AL) amyloidosis&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents.&#xD;
&#xD;
          -  Concurrent systemic treatment or prior therapy within 4 weeks for SMM (if a patient&#xD;
             has received any previous SMM therapy this must be discussed with the Principal&#xD;
             Investigator before inclusion in the trial).&#xD;
&#xD;
        Treatment with corticosteroids for other indications is permitted&#xD;
&#xD;
          -  Contraindication to any concomitant medication, including antivirals, anticoagulation&#xD;
             prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy&#xD;
&#xD;
          -  History of allergic reactions attributed to immunomodulatory agents and proteasome&#xD;
             inhibitors.&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Significant cardiovascular disease with NYHA grade III or IV symptoms, or hypertrophic&#xD;
             cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within 3 months&#xD;
             prior to enrollment, or unstable angina, or unstable arrhythmia&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  Known or suspected HIV infection&#xD;
&#xD;
          -  Incidence of gastrointestinal disease that would prevent absorption.&#xD;
&#xD;
          -  Significant neuropathy ≥Grade 3 or grade 2 with pain within 14 days of enrollment&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection.&#xD;
&#xD;
          -  History of other malignancy (apart from basal cell carcinoma of the skin, or in situ&#xD;
             cervix carcinoma) except if the patient has been free of symptoms and without active&#xD;
             therapy during at least 5 years&#xD;
&#xD;
          -  Major surgery within 1 month prior to enrollment&#xD;
&#xD;
          -  Pre-existing pulmonary, cardiac or renal impairement that prevents hydration measures&#xD;
             as described at paragraph 9.1.4&#xD;
&#xD;
          -  Any psychological, familial, sociological and geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Broijl</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC / HOVON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>A. Broijl, Dr.</last_name>
    <phone>+31 (0)10 7033123</phone>
    <email>a.broyl@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>H. Zanders</last_name>
    <phone>+31 10 7041560</phone>
    <email>hdc@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CZ-Brno-UHBRNO</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CZ-Ostrava-Poruba-FNO</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IT-Ancona-UMBERTOA</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IT-Bologna-MALPHIGI</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IT-Brescia-SPEDALICIVILI</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IT-Roma-SAPIENZA</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IT-Torino-MOLINETTE</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Den Bosch-JBZ</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Hoofddorp-SPAARNEGASTHUIS</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Leeuwarden-MCL</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Nijmegen-RADBOUDUMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-ERASMUSMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Sittard-Geleen-ZUYDERLAND</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Utrecht-UMCUTRECHT</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NO-Oslo-OSLOUH</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>HOVON website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

